A new HIV diagnosis can raise many questions about medications, prescriptions, testing, and what treatment involves. Today, HIV treatment usually begins with antiretroviral therapy (ART) as soon as possible after diagnosis. This guide explains how initial treatment is selected, the types of HIV medications available, prescription considerations, monitoring, costs, and questions commonly asked when starting care.
A newly diagnosed person will generally be connected with a healthcare provider who can confirm the diagnosis, assess overall health, and develop an initial treatment plan. HIV treatment is recommended for everyone with HIV, regardless of how long they have had the infection.
Current U.S. guidelines recommend starting antiretroviral therapy as soon as possible after diagnosis. Starting treatment promptly can help people reach viral suppression sooner and supports long-term health.
The first prescription is not necessarily based on one laboratory result. Healthcare professionals consider several factors before selecting a regimen, including viral load, CD4 count, resistance testing, other infections, existing medical conditions, potential drug interactions, pregnancy status when relevant, cost, access, and the person's ability to take the medication consistently.
HIV medications are called antiretroviral drugs, or ARVs. They work by interfering with different stages of HIV replication.
Rather than relying on one drug in most situations, HIV treatment generally uses a combination of medicines. Combination therapy helps suppress the virus and reduces the likelihood that HIV will develop resistance to treatment.
There are several classes of antiretroviral medications, including:
More than 30 antiretroviral drugs across multiple classes have received FDA approval for HIV treatment.
For someone newly diagnosed, the important issue is usually not choosing an individual drug from a long list. The healthcare provider selects an appropriate treatment regimen based on the person's circumstances.
For many adults and adolescents who are beginning HIV treatment, current U.S. guidelines favor regimens containing a second-generation integrase inhibitor combined with other antiretroviral medicines. Recommended options for many people include bictegravir-based or dolutegravir-based regimens.
Examples of commonly used initial approaches include:
These are examples of treatment approaches rather than prescriptions for an individual person. The appropriate medication depends on laboratory results, previous medication exposure, other health conditions, drug interactions, and other factors.
For example, dolutegravir/lamivudine is not appropriate in every newly diagnosed situation. The current guidelines identify circumstances involving hepatitis B, resistance testing, and rapid treatment initiation where another regimen may be preferred.
That distinction matters because two people with the same HIV diagnosis may not necessarily receive the same prescription.
Choosing an HIV medication prescription involves more than identifying a drug that suppresses HIV.
Healthcare professionals may consider:
Viral load: The amount of HIV RNA in the blood helps establish a baseline and monitor response to treatment.
CD4 count: This provides information about immune function and can influence certain treatment and preventive-care decisions.
Drug resistance: Resistance testing can help determine whether HIV has mutations that could reduce the effectiveness of particular medications.
Other infections: Hepatitis B, hepatitis C, tuberculosis, and other conditions can affect regimen selection.
Drug interactions: Prescription medications, over-the-counter products, supplements, and other treatments can interact with antiretroviral drugs.
Kidney and liver health: Some medications may require additional consideration when a person has kidney or liver problems.
Convenience and adherence: Dosing frequency, pill burden, formulation, and the ability to take medication consistently can all matter.
Cost and access: Insurance coverage, pharmacy availability, assistance programs, and the specific medication prescribed can affect the practical cost of treatment.
The goal is to identify a regimen that combines strong antiviral activity with a reasonable safety, interaction, dosing, and access profile for the individual.
People newly entering HIV care typically undergo laboratory testing to establish a baseline.
Important measurements include HIV viral load and CD4 cell count. Resistance testing is also used to help guide selection of an appropriate antiretroviral regimen.
Other testing may evaluate kidney and liver function and screen for conditions that could affect treatment decisions.
Importantly, waiting for every test result does not always mean treatment must be delayed. Current guidance supports rapid or immediate ART initiation in appropriate circumstances, with treatment adjusted later if additional information indicates that a different regimen would be better.
This is particularly important when someone has recently acquired HIV, because early treatment can provide clinical benefits and reduce the risk of transmission.
The price of HIV treatment can vary substantially depending on the medication, insurance coverage, pharmacy, formulation, and available assistance.
For someone with prescription insurance, the amount paid out of pocket may be very different from the medication's undiscounted price. Some people may also qualify for HIV medication assistance programs or other forms of financial support.
When comparing HIV medication costs, it is useful to consider the entire treatment arrangement rather than looking only at a medication's listed price.
Factors can include:
Cost and access are recognized considerations when selecting an HIV treatment regimen, but a lower-cost medication is not automatically the appropriate choice for every person.
Modern antiretroviral therapy can suppress HIV to very low or undetectable levels when taken consistently and when the regimen is effective for the individual.
The objective of treatment is sustained viral suppression, while also preserving immune function and supporting long-term health. Sustained viral suppression also prevents sexual transmission of HIV.
Treatment is not generally considered a cure. Instead, ART controls HIV by suppressing viral replication, which means treatment needs to continue as directed.
Regular follow-up helps determine whether the prescribed regimen is working. Viral load testing is an important part of monitoring treatment response, while CD4 testing helps assess immune function.
Someone researching HIV medications may encounter many different brands, combinations, formulations, and treatment approaches. Comparing them only by brand name can be misleading.
Instead, useful comparison factors include:
For some people, a single-tablet regimen may simplify treatment. For others, a different combination may be more appropriate because of resistance, hepatitis B status, kidney function, previous PrEP or PEP exposure, or another clinical factor.
The current guidelines specifically emphasize factors such as effectiveness, tolerability, pill burden, dosing frequency, drug interactions, cost, access, resistance results, and comorbid conditions when selecting initial therapy.
After the initial prescription is selected, treatment becomes an ongoing process rather than a one-time decision.
Follow-up appointments allow healthcare professionals to evaluate viral suppression, review potential adverse effects, assess adherence, and address changes in health or medication needs.
Someone starting treatment may also want to ask:
These questions can make the first few appointments more productive and help identify practical barriers before they interfere with treatment.
Many newly diagnosed adults begin an integrase inhibitor-based antiretroviral regimen. The exact prescription depends on factors such as resistance testing, viral load, hepatitis B status, other medical conditions, previous medication exposure, and potential interactions.
Yes. U.S. guidelines recommend starting ART immediately or as soon as possible after HIV diagnosis when clinically appropriate. Testing and evaluation can occur alongside treatment initiation rather than unnecessarily delaying therapy.
For most people, ART is ongoing treatment. Current guidance emphasizes continuing effective ART without interruption because stopping treatment can allow HIV to replicate again.
Healthcare professionals consider viral load, CD4 count, resistance testing, other infections, medical conditions, potential drug interactions, dosing requirements, cost, access, and other individual factors.
Yes. HIV treatment can sometimes be changed because of side effects, drug interactions, resistance, new health conditions, adherence challenges, or other considerations. Any change should be made with an HIV healthcare professional.
The primary goal is sustained viral suppression while preserving immune function and supporting long-term health. Effective viral suppression also prevents sexual transmission of HIV.